Accurate diagnostics with precision biomarker gene panels
Genetic biomarkers are particularly useful for oncology therapeutics. However, most approved drugs have a single variant biomarker. Heligenics offers whole gene biomarkers, where all variants with similar activity to an established biomarker can be used.
Five Facts
- Steady growth in genetic biomarkers over the last decade
- There are 100s of genetic biomarkers
- Genes have many variants with the same activity of known biomarkers
- Whole gene markers expand the number of customers for a drug
- one size doesn’t fit all
Treatments based on one genetic marker have medical advantages
Emergence of Genetic Biomarkers
• 46% of total recent approvals
• One mutation as a biomarker
From “The Personalized Medicine Report: 2017 Opportunity, Challenges, and the Future”.
http://www.personalizedmedicinecoalition.org
Whole Gene Biomarker
Example of patients with single mutation biomarker identified versus using GML whole gene biomarker panel
Single Mutation Biomarker
GML Whole Gene Biomarker
Disease, but lack Single
Mutation Biomarker
Disease with Single Mutation
Biomarker
Disease with Whole Gene
Biomarker
One Size Does Not Fit All
Percentage of the patient population for which a particular drug is NOT effective
Anti-Depressants
(SSRI’s)
Asthma Drugs
Diabetes Drugs
Arthritis Drugs
Alsheimer’s Drugs
Cancer Drugs
38%
40%
43%
50%
70%
75%
From Spear and Huff et al. Trends Mol Med 2001 Clinical application of pharmacogenetics.
“Precision” cancer therapeutics are based on a single genetic mutation
Heligenics whole gene biomarkers utilize the complete gene
Failed clinical trial – rescue an FDA rejection with whole gene biomarkers
Whole gene biomarkers examine all the mutations in a gene rather than a single mutation. This is a natural conceptual expansion of what is already being done.
Download a Whole Gene Biomarkers PDF
